Haemophilia : the official journal of the World Federation of Hemophilia · 2026
Population-Level Real-World Healthcare Costs in Men and Women With Haemophilia A.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hirniak Sam, Drover Samantha S M, Edginton Andrea N, Hajducek Dagmar M, Iorio Alfonso, Alsabbagh Mhd Wasem, Wong William W L
Аннотация
INTRODUCTION: Even with modern prophylaxis options, people living with haemophilia have significantly lower quality of life and joint health outcomes than those without.
AIM: Our goal was to determine if real-world health-system costs are higher for people living with haemophilia A compared to those without and determine how joint-health state impacts this cost.
METHODS: We utilized a population-level, retrospective study design using health administrative data to determine the impact of sex and joint-health states on cross-sectional cost. Cases were identified using diagnostic codes. Joint health states were determined in 30-day intervals by stepping forward and backward from joint replacement surgeries. Control groups were established through propensity score matching, aligning participants based on demographic, economic and health-related variables. Direct 30-day medical costs were generated in 2022 CAD. The impact of sex and disease health phases on direct healthcare system costs was analyzed through a two-part regression model.
RESULTS: 2341 eligible individuals with haemophilia A were identified. 26% were female. In pre-severe joint damage, mean 30-day costs were higher for patients with haemophilia A-$910 (standard deviation SD: $4069) for females and $724 (SD: $3577) for males, compared to $469 (±$2126) and $352 (±$2188) for matched controls, respectively. The regression model showed that current joint health state, number of other comorbidities, haemophilia status and sex were important factors within healthcare system cost.
CONCLUSIONS: The results of this study indicate that even with haemophilia treatment there remains an increased healthcare system cost for those with haemophilia A, regardless of sex.
AIM: Our goal was to determine if real-world health-system costs are higher for people living with haemophilia A compared to those without and determine how joint-health state impacts this cost.
METHODS: We utilized a population-level, retrospective study design using health administrative data to determine the impact of sex and joint-health states on cross-sectional cost. Cases were identified using diagnostic codes. Joint health states were determined in 30-day intervals by stepping forward and backward from joint replacement surgeries. Control groups were established through propensity score matching, aligning participants based on demographic, economic and health-related variables. Direct 30-day medical costs were generated in 2022 CAD. The impact of sex and disease health phases on direct healthcare system costs was analyzed through a two-part regression model.
RESULTS: 2341 eligible individuals with haemophilia A were identified. 26% were female. In pre-severe joint damage, mean 30-day costs were higher for patients with haemophilia A-$910 (standard deviation SD: $4069) for females and $724 (SD: $3577) for males, compared to $469 (±$2126) and $352 (±$2188) for matched controls, respectively. The regression model showed that current joint health state, number of other comorbidities, haemophilia status and sex were important factors within healthcare system cost.
CONCLUSIONS: The results of this study indicate that even with haemophilia treatment there remains an increased healthcare system cost for those with haemophilia A, regardless of sex.